Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.62 |
| ▸ | ACE | P12821 | 3/20 | 0.62 |
| ▸ | CPA1 | P15085 | 2/20 | 0.62 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | TERT | O14746 | 1/20 | 0.49 |
| ▸ | ECE1 | P42892 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 4/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10338209 | 1.00 | MME (0.62) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL8728266 | 1.00 | MME (0.62) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL30052810 | 0.93 | MME (0.56) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL30051655 | 0.88 | MME (0.54) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL30051352 | 0.87 | MME (0.53) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL30051565 | 0.85 | MME (0.51) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL26255783 | 0.85 | TERT (0.49) | MMEACECPA1ACE2TERT | |
| SCHEMBL30455467 | 0.84 | MME (0.50) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL30053138 | 0.83 | MME (0.49) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL12259750 | 0.82 | TERT (0.46) | MMEACECPA1ACE2TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709912-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | BioAtla, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| WO-2024232976-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | BIOATLA, INC. (US) | 2024-11-14 | — | — | WO | claimed |
| EP-4424365-A2 | PET FOOD COMPOSITIONS | Hill's Pet Nutrition, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| EP-4017281-B1 | PET FOOD COMPOSITIONS | HILLS PET NUTRITION INC (US) | 2024-08-28 | — | — | EP | claimed |
| US-12050228-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2024-07-30 | — | — | US | claimed |
| US-20240044046-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | BIOATLA, INC. (US) | 2024-02-08 | — | — | US | claimed |
| US-11892458-B2 | Biochemical predictors of red blood cell quality | BLOODWORKS NW (US) | 2024-02-06 | — | — | US | claimed |
| WO-2023233945-A1 | BILIARY TRACT CANCER TESTING METHOD | 株式会社日立ハイテク | 2023-12-07 | — | — | WO | claimed |
| US-20220282399-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | BIOATLA, INC. (US) | 2022-09-08 | — | — | US | claimed |
| CN-114828648-A | Pet food compositions | 希尔氏宠物营养品公司 | 2022-07-29 | — | — | CN | claimed |
| EP-4017281-A1 | PET FOOD COMPOSITIONS | Hill's Pet Nutrition, Inc. (US) | 2022-06-29 | — | — | EP | claimed |
| WO-2021127701-A1 | PET FOOD COMPOSITIONS | HILL'S PET NUTRITION, INC. (US) | 2021-06-24 | — | — | WO | claimed |
| US-20210088539-A1 | AUTOMATED SAMPLE QUALITY ASSESSMENT | METABOLON, INC. | 2021-03-25 | — | — | US | claimed |
| US-20210055313-A1 | BIOCHEMICAL PREDICTORS OF RED BLOOD CELL QUALITY | BLOODWORKS (US) | 2021-02-25 | — | — | US | claimed |
| US-10890592-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2021-01-12 | — | — | US | claimed |
| US-10830777-B2 | Biochemical predictors of red blood cell quality | BLOODWORKS (US) | 2020-11-10 | — | — | US | claimed |
| EP-3565846-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | Bioatla, LLC (US) | 2019-11-13 | — | — | EP | claimed |
| WO-2018129007-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | BIOATLA LLC (US) | 2018-07-12 | — | — | WO | claimed |
| US-20170067884-A1 | Method for the Early Detection of Autism Spectrum Disorder by use of Metabolic Biomarkers | GREENWOOD GENETIC CENTER | 2017-03-09 | — | — | US | claimed |
| WO-2026089754-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026089752-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108583-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | UNIV CALIFORNIA (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4709912-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | BioAtla, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260022384-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2026-01-22 | — | — | US | disclosed |
| US-20260009800-A1 | METHODS OF DIAGNOSIS AND GUIDING TREATMENT OF VULVOVAGINAL SYMPTOMS AND FEMALE SEXUAL DYSFUNCTION | UNIV ARIZONA (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250380721-A1 | Pet Food Compositions | HILL'S PET NUTRITION, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250295713-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES | DERMBIONT, INC. | 2025-09-25 | — | — | US | disclosed |
| WO-2024232976-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | BIOATLA, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2024191946-A1 | METHODS OF DIAGNOSIS AND GUIDING TREATMENT OF VULVOVAGINAL SYMPTOMS AND FEMALE SEXUAL DYSFUNCTION | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-09-19 | — | — | WO | disclosed |
| EP-4424365-A2 | PET FOOD COMPOSITIONS | Hill's Pet Nutrition, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-4017281-B1 | PET FOOD COMPOSITIONS | HILLS PET NUTRITION INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-12064459-B2 | Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes | DERMBIONT, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| EP-3967217-B1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | GLOBAL GENOMICS GROUP LLC (US) | 2024-08-14 | — | — | EP | disclosed |
| US-12050228-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240230622-A9 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240133865-A1 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-04-25 | — | — | US | disclosed |
| EP-3690439-B1 | A NONINVASIVE METHOD FOR MEASURING METABOLITES FOR SKIN HEALTH | PROCTER & GAMBLE (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20240044046-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | BIOATLA, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-11892458-B2 | Biochemical predictors of red blood cell quality | BLOODWORKS NW (US) | 2024-02-06 | — | — | US | disclosed |
| US-20240019417-A1 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-01-18 | — | — | US | disclosed |
| CN-110382543-B | Protein therapeutics for treating senescent cells | 生物蛋白有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230404951-A1 | Pet Food Compositions | HILL'S PET NUTRITION, INC. (US) | 2023-12-21 | — | — | US | disclosed |
| WO-2023233945-A1 | BILIARY TRACT CANCER TESTING METHOD | 株式会社日立ハイテク | 2023-12-07 | — | — | WO | disclosed |
| US-20230181621-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2023-06-15 | — | — | US | disclosed |
| US-11674948-B2 | Methods and systems for determining autism spectrum disorder risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220394999-A1 | Pet Food Compositions | HILL'S PET NUTRITION, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220282399-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | BIOATLA, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| CN-114828648-A | Pet food compositions | 希尔氏宠物营养品公司 | 2022-07-29 | — | — | CN | disclosed |
| EP-4017281-A1 | PET FOOD COMPOSITIONS | Hill's Pet Nutrition, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20220163538-A1 | METABOLITES AS DIAGNOSTICS FOR AUTISM SPECTRUM DISORDER IN CHILDREN WITH GASTROINTESTINAL SYMPTOMS | RENSSELAER POLYTECHNIC INSTITUTE | 2022-05-26 | — | — | US | disclosed |
| US-20220160617-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES | DERMBIONT, INC. | 2022-05-26 | — | — | US | disclosed |
| EP-3967217-A1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | Global Genomics Group, LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3954991-A2 | METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK | Laboratory Corporation of America Holdings (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3948277-A1 | METABOLITES AS DIAGNOSTICS FOR AUTISM SPECTRUM DISORDER IN CHILDREN WITH GASTROINTESTINAL SYMPTOMS | Arizona Board of Regents on behalf of Arizona State University (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20210386802-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES | DERMBIONT, INC. | 2021-12-16 | — | — | US | disclosed |
| US-20210361725-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES | DERMBIONT, INC. | 2021-11-25 | — | — | US | disclosed |
| EP-3650852-B1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | GLOBAL GENOMICS GROUP LLC (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20210230221-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | BIOATLA, LLC (US) | 2021-07-29 | — | — | US | disclosed |
| CN-113156096-A | Blood-based biomarkers for diagnosing coronary atherosclerotic disease | 全球基因集团有限责任公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3847257-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | Ospedale San Raffaele S.r.l. (IT) | 2021-07-14 | — | — | EP | disclosed |
| WO-2021127701-A1 | PET FOOD COMPOSITIONS | HILL'S PET NUTRITION, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-11040077-B2 | Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes | DERMBIONT, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210088539-A1 | AUTOMATED SAMPLE QUALITY ASSESSMENT | METABOLON, INC. | 2021-03-25 | — | — | US | disclosed |
| US-20210069268-A1 | METABOLOMIC REVISION OF MAMMALIAN INFANTS | Evolve Biosystems, Inc. (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2021045166-A1 | COMPOSITION CONTAINING THERMOSENSITIVE GEL AND OLIGOPEPTIDE, AND USE THEREOF | 国際先端技術総合研究所株式会社 | 2021-03-11 | — | — | WO | disclosed |
| EP-3151665-B1 | METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK | LABORATORY CORP AMERICA HOLDINGS (US) | 2021-03-10 | — | — | EP | disclosed |
| CN-107427221-B | Blood-based biomarkers for diagnosing coronary atherosclerotic disease | 全球基因集团有限责任公司 | 2021-03-09 | — | — | CN | disclosed |
| US-20210055313-A1 | BIOCHEMICAL PREDICTORS OF RED BLOOD CELL QUALITY | BLOODWORKS (US) | 2021-02-25 | — | — | US | disclosed |
| US-10890592-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-10830777-B2 | Biochemical predictors of red blood cell quality | BLOODWORKS (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200345799-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES | DERMBIONT, INC. | 2020-11-05 | — | — | US | disclosed |
| WO-2020206443-A1 | METABOLITES AS DIAGNOSTICS FOR AUTISM SPECTRUM DISORDER IN CHILDREN WITH GASTROINTESTINAL SYMPTOMS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2020-10-08 | — | — | WO | disclosed |
| EP-3690439-A1 | A NONINVASIVE METHOD FOR MEASURING METABOLITES FOR SKIN HEALTH | The Procter & Gamble Company (US) | 2020-08-05 | — | — | EP | disclosed |
| EP-3681521-A1 | METABOLOMIC REVISION OF MAMMALIAN INFANTS | Evolve Biosystems Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20200194126-A1 | SYSTEMS AND METHODS FOR PROFILING AND CLASSIFYING HEALTH-RELATED FEATURES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-06-18 | — | — | US | disclosed |
| EP-3650852-A1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | Global Genomics Group, LLC (US) | 2020-05-13 | — | — | EP | disclosed |
| EP-2972326-B1 | A NONINVASIVE METHOD FOR MEASURING METABOLITES FOR SKIN HEALTH | PROCTER & GAMBLE (US) | 2020-01-08 | — | — | EP | disclosed |
| EP-3565846-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | Bioatla, LLC (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-3242588-B1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | GLOBAL GENOMICS GROUP LLC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20190156919-A1 | DETERMINING RELATIONSHIPS BETWEEN RISKS FOR BIOLOGICAL CONDITIONS AND DYNAMIC ANALYTES | ARIVALE, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-10254272-B2 | Blood based biomarkers for diagnosing atherosclerotic coronary artery disease | Global Genomics Group, LLC (US) | 2019-04-09 | — | — | US | disclosed |
| WO-2019055718-A1 | METABOLOMIC REVISION OF MAMMALIAN INFANTS | Evolve Biosystems, Inc. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20180348199-A1 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2018-12-06 | — | — | US | disclosed |
| US-20180321267-A1 | AUTOMATED SAMPLE QUALITY ASSESSMENT | METABOLON, INC. (US) | 2018-11-08 | — | — | US | disclosed |
| US-20180320217-A1 | METHODS FOR SAMPLING AND MEASURING ORAL LAVAGE PROTEINS | THE PROCTER & GAMBLE COMPANY | 2018-11-08 | — | — | US | disclosed |
| US-20180314790-A1 | System, Method and Apparatus for Determining the Effect of Genetic Variants | METABOLON, INC. | 2018-11-01 | — | — | US | disclosed |
| US-20180252733-A1 | Biochemical Predictors of Red Blood Cell Quality | BLOODWORKS | 2018-09-06 | — | — | US | disclosed |
| US-10041932-B2 | Methods and systems for determining autism spectrum disorder risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2018-08-07 | — | — | US | disclosed |
| WO-2018129007-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | BIOATLA LLC (US) | 2018-07-12 | — | — | WO | disclosed |
| EP-2763703-B1 | CONTROL OF WHOLE BODY ENERGY HOMEOSTASIS BY MICRORNA REGULATION | MIRAGEN THERAPEUTICS INC (US) | 2018-02-14 | — | — | EP | disclosed |
| US-20170370954-A1 | Biomarkers for Fatty Liver Disease and Methods Using the Same | METABOLON, INC. | 2017-12-28 | — | — | US | disclosed |
| EP-3242588-A1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | Global Genomics Group, LLC (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-3221463-A1 | BIOMARKERS FOR FATTY LIVER DISEASE AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20170067884-A1 | Method for the Early Detection of Autism Spectrum Disorder by use of Metabolic Biomarkers | GREENWOOD GENETIC CENTER | 2017-03-09 | — | — | US | disclosed |
| WO-2017015660-A1 | PREVENTION AND TREATMENT OF AGING AND NEURODEGENERATIVE DISEASES | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-01-26 | — | — | WO | disclosed |
| US-9428749-B2 | Control of whole body energy homeostasis by microRNA regulation | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-08-30 | — | — | US | disclosed |
| US-20160202239-A1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | Global Genomics Group, LLC | 2016-07-14 | — | — | US | disclosed |
| WO-2016112337-A1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | Global Genomics Group, LLC (US) | 2016-07-14 | — | — | WO | disclosed |
| WO-2016081534-A1 | BIOMARKERS FOR FATTY LIVER DISEASE AND METHODS USING THE SAME | METABOLON, INC. (US) | 2016-05-26 | — | — | WO | disclosed |
| US-20160128961-A1 | DIETARY OMEGA-3 FATTY ACID DERIVED GLYCEROPHOSPHOLIPIDS TO TREAT NEUROPATHIC PAIN | UNIV LOMA LINDA (US) | 2016-05-12 | — | — | US | disclosed |
| US-20160091481-A1 | METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK | LABORATORY CORPORATION OF AMERICA HOLDINGS | 2016-03-31 | — | — | US | disclosed |
| US-20160091480-A1 | METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK | LABORATORY CORPORATION OF AMERICA HOLDINGS | 2016-03-31 | — | — | US | disclosed |
| EP-2972326-A2 | A NONINVASIVE METHOD FOR MEASURING METABOLITES FOR SKIN HEALTH | The Procter & Gamble Company (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9176113-B1 | Methods and systems for determining autism spectrum disorder risk | SYNAPDX CORPORATION (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150293072-A1 | METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK | LABORATORY CORPORATION OF AMERICA HOLDINGS | 2015-10-15 | — | — | US | disclosed |
| US-20150294081-A1 | METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK | LABORATORY CORPORATION OF AMERICA HOLDINGS | 2015-10-15 | — | — | US | disclosed |
| US-20150065366-A1 | Biomarkers for Bladder Cancer and Methods Using the Same | METABOLON, INC. | 2015-03-05 | — | — | US | disclosed |
| US-20140343865-A1 | Biomarkers for Kidney Cancer and Methods Using the Same | METABOLON, INC. | 2014-11-20 | — | — | US | disclosed |
| EP-2788763-A2 | BIOMARKERS FOR KIDNEY CANCER AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20140303236-A1 | CONTROL OF WHOLE BODY ENERGY HOMEOSTASIS BY MICRORNA REGULATION | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140296134-A1 | METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-10-02 | — | — | US | disclosed |
| WO-2014144223-A2 | A NONINVASIVE METHOD FOR MEASURING METABOLITES FOR SKIN HEALTH | THE PROCTER & GAMBLE COMPANY (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140271930-A1 | NONINVASIVE METHOD FOR MEASURING METABOLITES FOR SKIN HEALTH | THE PROCTER & GAMBLE COMPANY (US) | 2014-09-18 | — | — | US | disclosed |
| EP-2776832-A1 | BIOMARKERS FOR BLADDER CANCER AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2014-09-17 | — | — | EP | disclosed |
| EP-2776829-A1 | METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION | The Board of Regents of The University of Texas System (US) | 2014-09-17 | — | — | EP | disclosed |
| EP-2763703-A2 | CONTROL OF WHOLE BODY ENERGY HOMEOSTASIS BY MICRORNA REGULATION | Miragen Therapeutics (US) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013086365-A2 | BIOMARKERS FOR KIDNEY CANCER AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013070962-A1 | METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013070839-A1 | BIOMARKERS FOR BLADDER CANCER AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013052965-A2 | CONTROL OF WHOLE BODY ENERGY HOMEOSTASIS BY MICRORNA REGULATION | MIRAGEN THERAPEUTICS (US) | 2013-04-11 | — | — | WO | disclosed |
| US-5766556-A | SUITABLE ENVIRONMENT FOR SIMULTANEOUS SYNTHESIS OF ORGANIC COMPOUNDS, INORGANIC COMPOUNDS AND ORGANOMETALLIC COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1998-06-16 | — | — | US | disclosed |
| US-5714127-A | RESERVOIR RACKS WITH REACTION WELLS; GAS DISPERSION TUBES CONTAINING FILTERS; HOLDER BLOCK WITH APERTURES; MANIFOLD | WARNER-LAMBERT COMPANY (US) | 1998-02-03 | — | — | US | disclosed |
| US-5702672-A | REACTION TUBE COMPRISING GAS DISPERSION TUBE HAVING GROUNG GLASS JOINT SECTION | WARNER-LAMBERT COMPANY (US) | 1997-12-30 | — | — | US | disclosed |
| US-5612002-A | SYNTHESIS OF COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| US-5593642-A | CONTAINMENT OF SOLID SUPPORT WITHIN A GAS DISPERSION TUBE | WARNER-LAMBERT COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| US-5582801-A | HAVING PLURALITY OF REACTION TUBES WITH FILTERS ON LOWER ENDS, RESERVOIR WITH MEANS FOR RECEIVING FILTERS, HOLDER FOR SUPPORTING TUBES, MANIFOLD ENCLOSING UPPER ENDS, FASTENERS HOLDING TOGETHER HOLDER AND MANIFOLD, HOLDER AND RESERVOIR | WARNER-LAMBERT COMPANY (US) | 1996-12-10 | — | — | US | disclosed |
| US-5567391-A | MULTICOMPARTMENT CHEMICAL REACTORS | WARNER-LAMBERT COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5565173-A | USED FOR SOLID-PHASE SYNTHESIS | WARNER-LAMBERT COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1996030393-A1 | A METHOD FOR THE SYNTHESIS OF MIXTURES OF COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0663856-A1 | APPARATUS AND METHOD FOR MULTIPLE SIMULTANEOUS SYNTHESIS | WARNER-LAMBERT COMPANY (US) | 1995-07-26 | — | — | EP | disclosed |
| US-5324483-A | Apparatus for multiple simultaneous synthesis | WARNER-LAMBERT COMPANY (US) | 1994-06-28 | — | — | US | disclosed |
| WO-1994008711-A1 | APPARATUS AND METHOD FOR MULTIPLE SIMULTANEOUS SYNTHESIS | WARNER-LAMBERT COMPANY (US) | 1994-04-28 | — | — | WO | disclosed |
| WO-1994008711-A1 | APPARATUS AND METHOD FOR MULTIPLE SIMULTANEOUS SYNTHESIS | WARNER-LAMBERT COMPANY (US) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108583-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | MUC1, VIP, LGALS4 | MME 522/4885ACE 732/4885CPA1 138/4885 |
| US-20230181621-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | ASNS, GLS, GLS2 | MME 359/4885ACE 435/4885CPA1 432/4885 |
| US-20260009800-A1 | METHODS OF DIAGNOSIS AND GUIDING TREATMENT OF VULVOVAGINAL SYMPTOMS AND FEMALE SEXUAL DYSFUNCTION | SHBG, GNRHR, STIM2 | MME 2348/4885ACE 2490/4885CPA1 1442/4885 |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | IDO1, INMT, IDO2 | MME 3728/4885ACE 3985/4885CPA1 2441/4885 |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FGF23, FIBP, PTMS | MME 1131/4885ACE 2740/4885CPA1 440/4885 |
| US-20160202239-A1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | FABP3, APOB, CAD | MME 1037/4885ACE 271/4885CPA1 43/4885 |
| US-20260022384-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | ASNS, AARS1, NARS1 | MME 1489/4885ACE 1102/4885CPA1 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.